Allergies are a 500m patient market, but only 1% of patients are using immunotherapies. If or when that changes, ALK-Abelló will likely lead the market.
ALK-Abelló – Denmark’s next pharma highflyer?
read more
Weekly dispatches
Swen Lorenz
Nigeria – betting on Africa’s Milei?
Argentina is making headlines for planning radical reforms, but these are already happening in Nigeria. Will Nigerian equities go from value trap to growth play?
Hepsiburada – is Turkey’s “Amazon” a turnaround play?
Hepsiburada is the Amazon equivalent of Turkey. The New York-listed stock is down 90% since its IPO. Time to buy?
Sark – bidding for the Barclay estate and going public
The Sark Property Company is preparing an ambitious bid for real estate on Sark. The company also plans to do an IPO.
Scandinavian Tobacco – a comeback for cigars?
Alongside producing cigars, Scandinavian Tobacco Group produces plenty of cash for its shareholders – and it plans to grow further!
Allegro – a new cycle for the Polish e-commerce giant?
E-commerce company Allegro was Poland’s largest IPO ever. The stock has since dropped two-thirds. Is now the time to get in?
C&C Group – a rather unknown British market leader
C&C Group is a leading British producer and distributor of alcoholic drinks. There are several reasons why the stock should be re-rated.
Northern Data – to da moon, again?
The stock of Northern Data first rose tenfold, then dropped 96%. Will an event in Frankfurt trigger a new lift-off?
Hungary investor trip – what we learned
Two days of nonstop fact-finding in Hungary. Here is what you’ve missed.
Will Georgia’s EU membership candidate status bring further investment gains?
London-listed Georgian stocks have been on a tear. Is it still time to get into Bank of Georgia, TBC Bank and Georgia Capital?
A second opportunity at SNP?
Following a tender offer and leadership changes, the stock of SNP Schneider Neureither & Partner offers an interesting risk/reward ratio.
How Rolls-Royce benefits from the return of long-haul jets
The recovery of long-haul jet travel is boosting income at Rolls-Royce. The stock could have another 150% to run.
